- JP-listed companies
- Ownership
(4893) Shareholders
Market cap
¥6.4B
P/E ratio
Develops cancer immunotherapy treatments for solid tumors using proprietary PRIME technology that enhances immune cell activation and generates revenue through both in-house drug development and technology licensing.
大株主
| （単位：千株） | 2023/12 | 2024/12 | 2025/12 |
|---|---|---|---|
| 武田薬品工業 | 8,119.8 18.76% | 8,119.8 18.75% | 8,119.8 18.75% |
| 鶴亀 | 9,871.35 22.81% | 7,159.55 16.53% | 7,159.55 16.53% |
| 玉田 耕治 | 3,750 8.66% | 3,750 8.66% | 3,750 8.66% |
| KOREA SECURITIES DEPOSITORY-SAMSUNG | 3,678.22 8.49% | 3,678.72 8.49% | |
| 瀬戸 恭子 | 2,000 4.62% | 1,700 3.92% | 1,700 3.92% |
| 大和日台バイオベンチャー投資事業有限責任組合 | 1,349.2 3.11% | 1,349.2 3.11% | |
| 荻原 弘子 | 1,000 2.31% | 1,000 2.3% | 1,000 2.3% |
| 佐古田 幸美 | 1,000 2.31% | 1,000 2.3% | 1,000 2.3% |
| 和田 聡 | 1,970 4.55% | 956.9 2.2% | 956.9 2.2% |
| 石崎 秀信 | 760 1.75% | ||
| 石﨑 秀信 | 2,000 4.62% | 1,160 2.67% | |
| Binex Co., Ltd. | 2,277.825 5.26% | ||
| 大和日台バイオベンチャー 投資事業有限責任組合 | 1,349.2 3.11% | ||
| アプリコット | 1,203.85 2.78% | ||
| 計 | 34,542.025 79.81% | 29,873.67 68.98% | 29,474.17 68.06% |